Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder

Autism spectrum disorder (ASD) is a prevalent neurodevelopmental disorder with few medication options. Bumetanide, an FDA-approved diuretic, has been proposed as a viable candidate to treat core symptoms of ASD, however, neither the brain region related to its effect nor the cell-specific mechanism(...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hui Lv, Xiao Gu, Xingyue Shan, Tailin Zhu, Bingke Ma, Hao-Tian Zhang, Victorio Bambini-Junior, Tiantian Zhang, Wei-Guang Li, Xiaoling Gao, Fei Li
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2022-05-01
Edice:	Frontiers in Immunology
Témata:	autism spectrum disorder bumetanide nanoparticle social behavior microglia
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.870577/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!